On November 2, 2023 Heidelberg Pharma AG (FSE: HPHA) reported that it will present new findings of its clinical Phase I/IIa study with the proprietary ADC candidate HDP-101 at the 65th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) (Press release, Heidelberg Pharma, NOV 2, 2023, View Source [SID1234636763]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. András Strassz, Chief Medical Officer at Heidelberg Pharma, commented: "We are very pleased with the progress of patient enrollment in our clinical trial with HDP-101. So far, HDP-101 has shown to be safe and well tolerated, and we will continue dose escalation in the fifth patient cohort (100 µg/kg) as planned."
Poster title: HDP-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study
Presentation details
Abstract: #3334
Session: 652. Multiple Myeloma: Clinical and Epidemiological: Poster II
Time and location: Sunday, 10th December 2023, 6:00 pm – 8:00 pm PST, Hall G-H
Dr. Strassz will present the poster showing safety data and preliminary findings from four patient cohorts of the ongoing open-label, multicenter Phase I/IIa trial evaluating HDP-101 in multiple myeloma. He will also be available to answer questions.
HDP-101 is a BCMA antibody-Amanitin conjugate for the treatment of relapsed or refractory multiple myeloma, a bone marrow cancer with high unmet medical need. The first part of the trial is a Phase I dose escalation study to determine an optimal and safe dose of HDP-101 for the Phase II part of the study.
The first four patient cohorts and dose levels of the clinical study have been completed and proved to be safe and well tolerated. Currently, the trial is enrolling patients in the fifth cohort.